Dr Jane Wolstenholme
|Tel||+44 (0)1865 289269|
BA(Hons) (London), MSc (York), PhD (Nottingham)
Senior Health Economist, HERC
Jane Wolstenholme has 20 years of experience of conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. She has been a health economist at HERC since 1998.
Her main interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. She is principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care diagnostics. She is a health economics advisor for the RDS South Central and for the NIHR Diagnostics Evidence Co-Operative, Oxford. She supervises MSc and DPhil students. Jane has published widely and is co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.
Leal J. et al, (2018), Cancer Epidemiol, 52, 99 - 105
Translational health economics: The key to accountable adoption of in vitro diagnostic technologies.
Price CP. et al, (2018), Health Serv Manage Res, 31, 43 - 50
Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study
Wolstenholme JL. et al, (2017)
Estimating the variation in need for community-based social care by body mass index in England and associated cost: population-based cross-sectional study.
Copley VR. et al, (2017), BMC Public Health, 17
Including health economic analysis in pilot studies: lessons learned from a cost-utility analysis within the PROSPECTIV pilot study
Burns RM. et al, (2017), Global and Regional Health Technology Assessment